Tirzepatide Competitor Receives Clinical Trial Approval, Zhifei Biological Shares Surge Over 6% Intraday

Deep News2025-09-18

On September 18th during trading, shares of Chongqing Zhifei Biological Products Co.,Ltd. surged over 6% intraday following positive news announced the previous evening.

The company disclosed that CA111 injection, developed by its subsidiary Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA). The regulatory approval allows the company to conduct clinical trials in adults who are overweight or obese.

CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. According to the company's announcement, as of the disclosure date, only tirzepatide injection has been approved for market launch in China. Based on publicly available information, no other domestic products targeting the same mechanism have received market approval.

In the same announcement, Chongqing Zhifei Biological Products Co.,Ltd. noted that while the clinical trial approval for CA111 injection will not have a significant impact on the company's near-term performance, it will help strengthen the company's research and development capabilities and enhance its pipeline of investigational products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112561860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112561860","market":"us","top_or_hot":-1,"title":"Tirzepatide Competitor Receives Clinical Trial Approval, Zhifei Biological Shares Surge Over 6% Intraday","media":"Deep News","content":"<p>On September 18th during trading, shares of Chongqing Zhifei Biological Products Co.,Ltd. surged over 6% intraday following positive news announced the previous evening.</p>\n<p>The company disclosed that CA111 injection, developed by its subsidiary Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA). The regulatory approval allows the company to conduct clinical trials in adults who are overweight or obese.</p>\n<p>CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. According to the company's announcement, as of the disclosure date, only tirzepatide injection has been approved for market launch in China. Based on publicly available information, no other domestic products targeting the same mechanism have received market approval.</p>\n<p>In the same announcement, Chongqing Zhifei Biological Products Co.,Ltd. noted that while the clinical trial approval for CA111 injection will not have a significant impact on the company's near-term performance, it will help strengthen the company's research and development capabilities and enhance its pipeline of investigational products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tirzepatide Competitor Receives Clinical Trial Approval, Zhifei Biological Shares Surge Over 6% Intraday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTirzepatide Competitor Receives Clinical Trial Approval, Zhifei Biological Shares Surge Over 6% Intraday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-18 14:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On September 18th during trading, shares of Chongqing Zhifei Biological Products Co.,Ltd. surged over 6% intraday following positive news announced the previous evening.</p>\n<p>The company disclosed that CA111 injection, developed by its subsidiary Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA). The regulatory approval allows the company to conduct clinical trials in adults who are overweight or obese.</p>\n<p>CA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. According to the company's announcement, as of the disclosure date, only tirzepatide injection has been approved for market launch in China. Based on publicly available information, no other domestic products targeting the same mechanism have received market approval.</p>\n<p>In the same announcement, Chongqing Zhifei Biological Products Co.,Ltd. noted that while the clinical trial approval for CA111 injection will not have a significant impact on the company's near-term performance, it will help strengthen the company's research and development capabilities and enhance its pipeline of investigational products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1112561860","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112561860","pubTimestamp":1758176628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On September 18th during trading, shares of Chongqing Zhifei Biological Products Co.,Ltd. surged over 6% intraday following positive news announced the previous evening. The company disclosed that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300122":"智飞生物","BK0046":"生物疫苗","BK0239":"医药制造","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0188":"融资融券","BK0196":"行业龙头","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0077":"质押式回购","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC"},"translate_title":"替西帕肽竞争对手获临床试验批件智飞生物股价盘中大涨超6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300122":1},"content_text":"On September 18th during trading, shares of Chongqing Zhifei Biological Products Co.,Ltd. surged over 6% intraday following positive news announced the previous evening.\nThe company disclosed that CA111 injection, developed by its subsidiary Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA). The regulatory approval allows the company to conduct clinical trials in adults who are overweight or obese.\nCA111 injection is a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. According to the company's announcement, as of the disclosure date, only tirzepatide injection has been approved for market launch in China. Based on publicly available information, no other domestic products targeting the same mechanism have received market approval.\nIn the same announcement, Chongqing Zhifei Biological Products Co.,Ltd. noted that while the clinical trial approval for CA111 injection will not have a significant impact on the company's near-term performance, it will help strengthen the company's research and development capabilities and enhance its pipeline of investigational products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112561860","isCrawlerRequest":true}